2-(二乙氧基甲基)-1H-咪唑 | 13750-84-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 2-(二乙氧基甲基)-1H-咪唑
• 英文名称: 2-(diethoxymethyl)imidazole
• 英文别名: 2-diethoxymethyl-1H-imidazole；2-(Diethoxymethyl)-1H-imidazole
• CAS: 13750-84-0
• 化学式: C₈H₁₄N₂O₂
• 分子量: 170.211
• InChiKey: GDYWVVQIJJWUFA-UHFFFAOYSA-N

物化性质

• 保留指数：
  1091

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  12
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  47.1
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933290090

反应信息

• 作为反应物：
  描述：

  2-(二乙氧基甲基)-1H-咪唑 在 sodium hydroxide 、 sodium hypochlorite 作用下， 反应 0.17h， 生成 4,5-dichloroimidazole-2-carboxaldehyde diethyl acetal
  参考文献：
  名称：

  Synthesis of some dihydroxyphenyl 4,5-dichloroimidazol-2-yl ketones: compounds related to pyoluteorin

  摘要：

  DOI：

  10.1021/jo00132a045
• 作为产物：
  描述：

  N-(2,2-diethoxyethyl)-2,2-diethoxyacetamidine hydrochloride 在 对甲苯磺酸 作用下， 反应 1.0h， 以63%的产率得到2-(二乙氧基甲基)-1H-咪唑
  参考文献：
  名称：

  Synthesis of some dihydroxyphenyl 4,5-dichloroimidazol-2-yl ketones: compounds related to pyoluteorin

  摘要：

  DOI：

  10.1021/jo00132a045

文献信息

• [EN] CATALYSTS FOR THE TRANSFORMATION OF CARBON DIOXIDE AND GLYCEROL TO FORMIC ACID AND LACTIC ACID AND METHODS OF MAKING THE SAME<br/>[FR] CATALYSEURS POUR LA TRANSFORMATION DE DIOXYDE DE CARBONE ET DE GLYCÉROL EN ACIDE FORMIQUE ET EN ACIDE LACTIQUE ET LEURS PROCÉDÉS DE FABRICATION
  申请人：UNIV GEORGE WASHINGTON

  公开号：WO2018213821A1

  公开（公告）日：2018-11-22

  Catalysts and methods for transformation of glycerol and a carbon feedstock, such as CO2, a carbonate salt or a bicarbonate salt, are described herein. Homogeneous catalysts include compounds of formula M[NHC-R-linker]aLbXc, where M is a transition metal, NHC is an N-heterocyclic carbene ligand, R is an alkyl or aryl group, linker is a polar group, L is a neutral ligand, X is an anionic ligand, a ranges from 1-3, b ranges from 0-3, and c ranges from 0-3. Heterogeneous catalysts include a solid support with a catalytically active compound immobilized on the solid support, where the catalytically active compound has the formula M[NHC-R-linker]aLbXc where M is a transition metal, NHC is an N-heterocyclic carbene ligand, R is an alkyl or aryl group; linker is a polar group, L is a neutral ligand, X is an anionic ligand, a ranges from 1-3, b ranges from 0-3, and c ranges from 0-3.

  本文描述了用于转化甘油和碳原料（如CO2、碳酸盐或碳酸氢盐）的催化剂和方法。均相催化剂包括具有M[NHC-R-linker]aLbXc式化合物的化合物，其中M是过渡金属，NHC是N-杂环卡宾配体，R是烷基或芳基，linker是极性基团，L是中性配体，X是阴离子配体，a范围为1-3，b范围为0-3，c范围为0-3。非均相催化剂包括具有固体支撑物的催化活性化合物固定在固体支撑物上，其中催化活性化合物具有M[NHC-R-linker]aLbXc式化合物，其中M是过渡金属，NHC是N-杂环卡宾配体，R是烷基或芳基；linker是极性基团，L是中性配体，X是阴离子配体，a范围为1-3，b范围为0-3，c范围为0-3。
• Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives
  申请人：Galley Guido

  公开号：US20070197621A1

  公开（公告）日：2007-08-23

  The present invention relates a method for treating depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders which comprises administering to an individual a therapeutically effective amount of a compound of formula I wherein R, R 1 , R 2 , A and n are as defined in the specification and to their pharmaceutically active salts. The invention also relates to novel compounds of formula I, pharmaceutical compositions containing them, and methods for their preparation.

  本发明涉及一种治疗抑郁症、焦虑症、双相情感障碍、注意力缺陷多动障碍、压力相关障碍、精神分裂症等精神障碍、帕金森病等神经系统疾病、阿尔茨海默病等神经退行性疾病、癫痫、偏头痛、高血压、物质滥用、进食障碍、糖尿病、糖尿病并发症、肥胖症、血脂异常、能量消耗和吸收障碍、体温稳态障碍、睡眠和昼夜节律障碍以及心血管疾病的方法，包括向个体施用化合物I的治疗有效量，其中R、R1、R2、A和n如规范中所定义，以及其药用活性盐。该发明还涉及化合物I的新颖化合物、含有它们的药物组合物以及它们的制备方法。
• [EN] INHIBITORS OF PROTEASE-ACTIVATED RECEPTOR-2<br/>[FR] INHIBITEURS DU RÉCEPTEUR-2 ACTIVÉ PAR UNE PROTÉASE
  申请人：ASTRAZENECA AB

  公开号：WO2017194716A1

  公开（公告）日：2017-11-16

  The present application relates to certain substituted imidazole and triazole compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating pain, musculoskeletal inflammation, neuroinflammatory disorders, airway inflammation, itch, dermatitis, colitis and related conditions. The compounds are of Formula (I) where X is N or CH, Z and Y are N or C (but both not N) and R1-R3 are as defined herein.

  本申请涉及某些取代咪唑和三唑化合物，包含它们的药物组合物，以及使用它们的方法，包括用于治疗疼痛、肌肉骨骼炎症、神经炎症性疾病、气道炎症、瘙痒、皮炎、结肠炎和相关疾病的方法。这些化合物的化学式为（I），其中X为N或CH，Z和Y为N或C（但都不是N），R1-R3如下所定义。
• Oxidative radical cyclisations onto imidazoles and pyrroles using Bu3SnH
  作者：Fawaz Aldabbagh、W.Russell Bowman、Emma Mann

  DOI：10.1016/s0040-4039(97)10052-1

  日期：1997.11

  Oxidative radical cyclisation using Bu3SnH has been used for the synthesis of [1,2-c]-fused imidazoles and [1,2-a]-fused pyrroles from imidazolecarbaldehydes and acylpyrroles respectively. The intermediate nucleophilic N-alkyl radicals cyclise onto imidazole and pyrrole rings followed by oxidative re-aromatisation. (C) 1997 Elsevier Science Ltd.
• Bu3SnH mediated oxidative radical cyclisation onto imidazoles and pyrroles
  作者：Fawaz Aldabbagh、W.Russell Bowman、Emma Mann、Alexandra M.Z. Slawin

  DOI：10.1016/s0040-4020(99)00419-6

  日期：1999.6

  A new protocol using radical cyclisation has been developed for the synthesis of [1,2-c]-fused imidazoles and [1,2-a]-fused pyrroles. The intermediate nucleophilic N-alkyl radicals, generated using Bu3SnH from N-(omega-bromoalkyl) or N-[omega-(phenylselanyl)alkyl] imidazoles and pyrroles, undergo regioselective radical cyclisation onto the azole rings followed by oxidative re-aromatisation, (C) 1999 Elsevier Science Ltd. Ail rights reserved.